Kailera Therapeutics, Inc. (KLRA)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
19.01 USD
-0.96
(-4.807%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:53 a.m. EDT
The immediate outlook remains heavily skewed toward caution due to the company's complete lack of profitability and negative earnings per share, which renders traditional valuation metrics like P/E meaningless. While the balance sheet appears robust on paper with significant cash reserves relative to debt, the operating cash flow is deeply negative, indicating a heavy burn rate typical of early-stage biotech firms rather than sustainable cash generation. The recent price action shows volatility without a clear upward trend, trading near its 52-week lows despite a 'strong buy' analyst consensus that likely hinges on future clinical milestones rather than current financial performance. Without any dividend history or payout, income investors are entirely excluded, leaving the investment thesis purely speculative on future drug approvals. The absence of multi-year price history prevents a definitive judgment on long-term market validation, but the current fundamentals suggest a high-risk venture where capital preservation is difficult. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.869 |
| Market Cap | 2,463,042,304 |
| Forward P/E | -4.64 |
| Website | https://www.kailera.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2319231 |
| Address1 | 180 Third Avenue |
| Address2 | 4th Floor |
| All Time High | 28.23 |
| All Time Low | 18.5 |
| Ask | 24.37 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 790,700 |
| Average Daily Volume3 Month | 951,683 |
| Average Volume | 951,683 |
| Average Volume10Days | 790,700 |
| Bid | 14.38 |
| Bid Size | 2 |
| Book Value | -14,425.533 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 19.01 |
| Current Ratio | 9.671 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 20.09 |
| Day Low | 19.0 |
| Debt To Equity | 1.869 |
| Display Name | Kailera Therapeutics |
| Earnings Timestamp End | 1,786,132,800 |
| Earnings Timestamp Start | 1,786,132,800 |
| Ebitda | -222,194,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.262 |
| Enterprise Value | 2,946,702,336 |
| Eps Current Year | -3.97142 |
| Eps Forward | -4.09718 |
| Eps Trailing Twelve Months | -1.78 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.4624 |
| Fifty Day Average Change | -2.4524002 |
| Fifty Day Average Change Percent | -0.11426496 |
| Fifty Two Week Change Percent | -23.19231 |
| Fifty Two Week High | 28.23 |
| Fifty Two Week High Change | -9.219999 |
| Fifty Two Week High Change Percent | -0.32660288 |
| Fifty Two Week Low | 18.5 |
| Fifty Two Week Low Change | 0.5100002 |
| Fifty Two Week Low Change Percent | 0.02756758 |
| Fifty Two Week Range | 18.5 - 28.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,776,432,600,000 |
| Float Shares | 58,400,402 |
| Forward Eps | -4.09718 |
| Forward P E | -4.6397767 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 145 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.44941002 |
| Implied Shares Outstanding | 129,565,608 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-04-17 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts. |
| Long Name | Kailera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,463,042,304 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1899116257 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -209,836,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,587,425,191 |
| Number Of Analyst Opinions | 5 |
| Open | 20.0 |
| Operating Cashflow | -170,319,008 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 781 317 0290 |
| Previous Close | 19.97 |
| Price Eps Current Year | -4.786701 |
| Price Hint | 2 |
| Price To Book | -0.0013178022 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.526 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.959999 |
| Regular Market Change Percent | -4.80721 |
| Regular Market Day High | 20.09 |
| Regular Market Day Low | 19.0 |
| Regular Market Day Range | 19.0 - 20.09 |
| Regular Market Open | 20.0 |
| Regular Market Previous Close | 19.97 |
| Regular Market Price | 19.01 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 309,002 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 129,565,608 |
| Shares Percent Shares Out | 0.039300002 |
| Shares Short | 5,097,048 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,688,249 |
| Short Name | Kailera Therapeutics, Inc. |
| Short Percent Of Float | 0.039300002 |
| Short Ratio | 4.9 |
| Source Interval | 15 |
| State | MA |
| Symbol | KLRA |
| Target High Price | 57.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 42.6 |
| Target Median Price | 42.0 |
| Total Cash | 519,174,016 |
| Total Cash Per Share | 4.007 |
| Total Debt | 10,470,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.91339 |
| Two Hundred Day Average Change | -2.903389 |
| Two Hundred Day Average Change Percent | -0.13249384 |
| Type Disp | Equity |
| Volume | 309,002 |
| Website | https://www.kailera.com |
| Zip | 2,451 |